Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05213676 · ClinicalTrials.gov registry record · Phase 4

De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia

A Phase 4 study of Congenital Diaphragmatic Hernia, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
Phase 4
Development phase
600
Enrollment target
19
Study locations

NCT05213676 is a Phase 4 study of Congenital Diaphragmatic Hernia that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 600 participants, above the 169-participant average among 22 other Congenital Diaphragmatic Hernia trials with a reported enrollment target (255% higher). The trial reports 19 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05213676, a Phase 4 study of Congenital Diaphragmatic Hernia, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
Phase 4
Development phase
600 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to determine if de-implementation of inhaled nitric oxide (iNO) in the post-natal resuscitation/stabilization phase affects the composite outcome of extracorporeal life support (ECLS) use and/or mortality, as well as ECLS use, mortality, and/or oxygenation in congenital diaphragmatic hernia (CDH) newborns and to establish the cost-effectiveness of de-implementing iNO as a therapy in the postnatal resuscitation/stabilization phase of CDH management, which will be assessed as the incremental health system costs (savings) per prevented ECLS use and/or death.

Interventions

  • DRUG Inhaled Nitric Oxide (iNO) use
  • OTHER De-implementation of Inhaled Nitric Oxide (iNO) use

Study Locations (19)

California

  • University of California-Irvine & Children's Hospital of Orange County (UC-CHOC) - Irvine
  • University of Southern California & Children's Hospital Los Angeles (USC-CHLA) - Los Angeles
  • Stanford University & Lucile Packard Children's Hospital (Stanford-LPCH) - Palo Alto
  • University of California, San Diego & Rady Children's Hospital (UCSD-Rady) - San Diego

Tennessee

  • University of Tennessee & LeBonheur Children's Hospital (UT-LBCH) - Memphis
  • Vanderbilt University & Vanderbilt University Medical Center (VUMC) - Nashville

Alabama

  • University of Alabama & Children's Hospital of Alabama (UAB-CoA) - Birmingham

Arkansas

  • University of Arkansas & Arkansas Children's Hospital (UA-ACH) - Little Rock

Colorado

  • University of Colorado & Children's Hospital of Colorado (CU-CHC) - Aurora

Georgia

  • Emory University & Children's Healthcare of Atlanta (CHOA) - Atlanta

Indiana

  • Indiana University & Riley Children's Hospital (IU-RiCH) - Indianapolis

Kentucky

  • University of Louisville & Norton Children's Hospital (UL-NCH) - Louisville

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-11-01
Est. Completion 2031-04-30
Phase Phase 4

What the Registry Record Tells You About NCT05213676

The ClinicalTrials.gov registry entry for NCT05213676 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 169-participant average among 22 other Congenital Diaphragmatic Hernia trials with a reported enrollment target (255% higher). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congenital Diaphragmatic Hernia appearing as the primary indexed condition, and to 2 interventions - of which Inhaled Nitric Oxide (iNO) use is the first listed.

NCT05213676 reports 19 study locations spanning 15 distinct geographic areas - top geographies include California, Tennessee, Alabama.

Frequently Asked Questions

What is clinical trial NCT05213676 about?

NCT05213676 is a clinical study titled "De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia". The purpose of this study is to determine if de-implementation of inhaled nitric oxide (iNO) in the post-natal resuscitation/stabilization phase affects the composite outcome of extracorporeal life support (ECLS) use and/or mortality, as well as ECLS use, mortality, and/or oxygenation in congenital ...

What is the current status of trial NCT05213676?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2025-11-01. Estimated completion is 2031-04-30.

What conditions does trial NCT05213676 study?

This clinical trial studies the following conditions: Congenital Diaphragmatic Hernia.

What interventions are being tested in trial NCT05213676?

The interventions under investigation include: Inhaled Nitric Oxide (iNO) use (DRUG), De-implementation of Inhaled Nitric Oxide (iNO) use (OTHER).

Who is sponsoring clinical trial NCT05213676?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05213676 being conducted?

This trial has 19 study locations across Alabama, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Diaphragmatic Hernia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.